首页> 美国卫生研究院文献>Cancer Medicine >Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades

【2h】

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades

机译：改善3760名淋巴瘤患者的生存：过去20年的学术中心经验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The treatment outcomes and prognosis of lymphoma are affected by various factors such as hospital types. This study was to describe the temporal trend in the survival of lymphoma in an academic center in China.

机译：淋巴瘤的治疗结果和预后受多种因素影响，例如医院类型。这项研究旨在描述中国某学术中心淋巴瘤生存的时间趋势。

著录项

期刊名称 Cancer Medicine
作者
Weiping Liu; Xinqiang Ji; Yuqin Song; Xiaopei Wang; Wen Zheng; Ningjing Lin; Meifeng Tu; Yan Xie; Lingyan Ping; Zhitao Ying; Chen Zhang; Lijuan Deng; Meng Wu; Feier Feng; Xin Leng; Yingli Sun; Tingting Du; Jun Zhu;
展开▼
作者单位

展开▼
年(卷),期 2020(9),11
年度 2020
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Hodgkin disease; lymphoma; lymphoma; non‐Hodgkin; prognosis; survival;

机译：霍奇金病;淋巴瘤;淋巴瘤;非霍奇金病;预后;生存;

相似文献

外文文献
中文文献
专利

1. 陈红风运用扶正法改善TNBC患者生存质量及其基于数据挖掘的经验研究 [J] . 张玉柱, 周悦, 时百玲, 数字中医药(英文) . 2018,第004期
2. 陈红风运用扶正法改善TNBC患者生存质量及其基于数据挖掘的经验研究 [J] . 张玉柱, 周悦, 时百玲, 数字中医药（英文） . 2018,第004期
3. Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades [J] . Weiping Liu, Xinqiang Ji, Yuqin Song, Cancer Medicine . 2020,第11期

机译：提高3760例淋巴瘤患者的存活：二十年多年学术中心的经验
4. Improving Survival of Patients With Hodgkin Lymphoma Over 4 Decades: Experience of the British National Lymphoma Investigation (BNLI) With 6834 Patients [J] . Kwan Amy, Chadwick Nick, Hancock Barry Clinical lymphoma, myeloma & leukemia . 2017,第2期

机译：40多年来改善霍奇金淋巴瘤患者的存活：英国国家淋巴瘤调查（BNLI）的经验，6834名患者
5. Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature [J] . A. Prica, A. Pratzer, M. Cheung, Journal of Cancer Therapy . 2015,第1期

机译：利妥昔单抗提高了CODOX-M / IVAC治疗Burkitt淋巴瘤（BL）和B细胞淋巴瘤的患者的总体生存率，这是无法分类的，其特征为弥漫性大型B细胞淋巴瘤和BL（BCL-U）：文献回顾
6. Survival Prediction in Patients with Diffuse Large B-cell Lymphoma Using Logistic and Neural Network Models [C] . Chin-Chuan Chang, Chien-Hua Chen, Jer-Guang Hsieh, IEEE Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability . 2021

机译：逻辑和神经网络模型弥漫性大B细胞淋巴瘤患者的存活预测
7. Prognostic Biomarkers for Diffuse Large B Cell Lymphoma Patient Survival after Treatment with Chemotherapy: A Retrospective Analysis of 88 Cases [D] . Bushra, Hamama tul. 2019

机译：弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物：88例回顾性分析
8. Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers [O] . Tanya M. Wildes, Laura Farrington, Cecilia Yeung, 2014

机译：利妥昔单抗与伯基特淋巴瘤的生存改善有关：来自美国两个学术医学中心的回顾性分析
9. MP54-17 DO PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING BLADDER-PRESERVING RADIOTHERAPY/CHEMORADIOTHERAPY AT ACADEMIC CENTERS HAVE IMPROVED SURVIVAL OUTCOMES COMPARED TO THOSE TREATED AT NON-ACADEMIC CENTERS? [O] . Amishi Bajaj, Robert Blackwell, Brendan Martin, 2017

机译：MP54-17患有在学术中心进行膀胱侵蚀性膀胱癌的患者患有膀胱侵袭性膀胱癌，与非学术中心治疗的人有改善的生存结果吗？

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades

摘要

著录项

相似文献

相关主题

期刊订阅